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Abstract: We investigated whether longitudinal patterns in antithrombotic therapy have changed
after the introduction of non-vitamin K oral anticoagulants (NOACs) in patients with atrial fibrillation
(AF) who underwent percutaneous coronary intervention (PCI). Using a claims database of the Korean
AF population who underwent PCI between 2012 and 2016 (n = 18,691), we analyzed prescription
records of oral anticoagulants (OACs) and antiplatelets at 3-month intervals over 2 years after PCI.
The study population was stratified (pre-NOAC, transition, and NOAC era) using time-periods of
NOAC introduction in Korea and an expansion of reimbursement for NOAC in AF as indicators. The
overall rates of OAC were low at baseline (24.9%, 26.9%, and 35.2% in pre-NOAC, transition, and
NOAC era, respectively), contrary to high rates of dual antiplatelet therapy (DAPT) (73.3%, 71.4%,
and 63.6%). However, OAC prescription rates were increased at 1-year (18.5%, 22.5%, and 31.6%),
and 2-year follow-up (17.8%, 24.2%, and 31.8%) from pre-NOAC to NOAC era. In NOAC era, 63.5%
of baseline OAC prescriptions comprised NOAC, of which 96.4% included triple therapy with DAPT.
Over 2 years, we observed increasing rates of double therapy with a single antiplatelet (18.3% and
20.0% at 1- and 2-year follow-up) and OAC monotherapy (2.7% and 8.9% at 1- and 2-year follow-up).
Keywords: atrial fibrillation; percutaneous coronary intervention; anticoagulation; antiplatelets;
non-vitamin K oral anticoagulant
1. Introduction
Combination therapy with anticoagulants and antiplatelets has been a major con-
sideration in treatment decisions for patients with atrial fibrillation (AF) who undergo
percutaneous coronary intervention (PCI) [1,2]. Guidelines recommend the initial adminis-
tration of oral anticoagulants (OACs) for stroke prevention in addition to dual antiplatelet
therapy (DAPT) after PCI (triple therapy (OACs plus DAPT)) [1,2]. However, the aug-
mented risk of major bleeding associated with combination therapy may counterbalance
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the treatment benefits [3], and clinicians might be hesitant to administer guideline-based an-
tithrombotic therapy after PCI [4,5]. Therefore, careful evaluation of treatment compliance
is important in real-world clinical practice to guide clinicians for optimal management. A
nationwide study can provide valuable longitudinal data regarding antithrombotic therapy
in patients with AF who undergo PCI, because this information will aid in evaluation of
long-term compliance [6]. Since non-vitamin K oral anticoagulants (NOACs) have been
the major choice for stroke prevention in AF, a growing body of evidence has reported
the outcome benefit of a combination regimen based on NOACs for patients with AF
undergoing PCI [7–10]. Therefore, for those eligible for NOACs, guidelines recommend
NOACs in preference to vitamin K antagonists (VKAs) in a combination regimen with
antiplatelet therapy after PCI [1,2]. The current study was purposed to investigate whether
the updated guidelines have changed the long-term treatment patterns in antithrombotic
therapy among the AF population after PCI.
2. Materials and Methods
2.1. Study Population
Clinical data of the study population were obtained from the claims database of the
Korean Health Insurance Review and Assessment Service (HIRA). The HIRA includes
comprehensive details regarding complete medical healthcare utilization and cost data
from primary care health services, pharmacies, and hospitals that cater to the entire Korean
population [6]. The original database can be accessed via request through the Healthcare
Bigdata Hub (https://opendata.hira.or.kr (accessed on 1 June 2020)) of the HIRA. From
the database, we included patients with AF who underwent PCI between 2012 and 2016.
Patients with AF were defined based on the International Classification of Diseases, Tenth
Revision, Clinical Modification (ICD-10-CM) codes I48.0–48.4 and I48.9, excluding those
with mitral stenosis (I50, I52, and I59) or prosthetic heart valves (Z952–Z954). Among
patients with AF, we identified those who underwent PCI after the diagnosis of AF using
the procedure codes for coronary intervention: M6551–6552, M6561–6564, and M6571–
6572. We excluded patients who died before discharge and those for whom follow-up
medication records were unavailable. Finally, we analyzed the data of 18,691 patients.
NOACs were introduced in Korea in 2013 and have been widely used only since July 2015
after the expansion of the reimbursement criteria was adopted in Korea [4]. Therefore, we
categorized the study population into the following cohorts based on the period of study
inclusion: the pre-NOAC era (January 2012–June 2013), the transition era (July 2013–June
2015), and the NOAC era (July 2015–December 2016). The study was approved by the
Seoul National University Hospital Institutional Review Board (E-1911-052-1078). Informed
consent was waived by the review board as each patient is de-identified and encrypted in
the HIRA database to protect patient privacy.
2.2. Antithrombotic Therapies
We reviewed prescription records of antithrombotic therapy, including OACs (VKAs
or NOACs) and antiplatelet agents (aspirin and P2Y12 inhibitors comprising clopidogrel,
prasugrel, and ticagrelor) for all patients in each cohort at a 3-month interval from the index
PCI over a 2-year follow-up period. Based on prescription records, we categorized patients
into the following groups: (1) triple therapy (VKAs or NOACs plus DAPT), (2) double
therapy (VKAs or NOACs plus single antiplatelet therapy (SAPT)), (3) OACs monotherapy
(VKAs or NOACs only), (4) DAPT, and (5) SAPT. Patients who died before 2 years or those
who underwent repeat PCI before 2 years were censored at the event date.
2.3. Clinical Risk Factors
Detailed definitions of comorbidities and risk scores are summarized in Table S1.
Hypertension and diabetes mellitus were defined based on both diagnostic codes and
prescription claims for at least a single antihypertensive or antidiabetic drug, respectively.
Congestive heart failure, stroke, systemic thromboembolism, myocardial infarction (MI),
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gastrointestinal (GI) bleeding, intracranial hemorrhage, and chronic liver or renal disease
were defined based on ICD-10-CM codes. CHA2DS2-VASc scores were calculated for each
patient to assess individual stroke risk. Data for the labile international normalized ratio
and alcohol use are unavailable in the HIRA database. Therefore, we defined modified
HAS-BLED scores after excluding these variables to assess the individual bleeding risk.
2.4. Statistical Analysis
An inter-cohort difference of baseline characteristics was assessed using one-way
analysis of variance and Kruskal–Wallis test for continuous variables and chi-square tests
for categorical variables, with multiple testing adjustments for pairwise comparison. We
performed an inter-cohort comparison of the prescription rates of overall OACs and
NOACs at 3-month intervals using the chi-square test. Therefore, we could analyze the
2-year patterns in antithrombotic therapy within each cohort and record any significant
changes in these longitudinal treatment patterns from the pre-NOAC to the NOAC era.
In the previous nationwide study performed in the VKAs era [5], we observed that
female sex, prior MI, and baseline DAPT use were independently associated with no
OACs use 1 year after PCI. We also observed that most patients who received OACs
were administered combination therapy that included antiplatelet agents instead of OAC
monotherapy 1 year post-PCI. Therefore, we performed multivariable logistic regression
analysis to identify the clinical factors associated with OAC use 1 year after PCI in the
NOAC era. Additionally, we investigated the positive predictors of the preference for OAC
monotherapy over combination regimens or antiplatelet-only therapy 1 year after PCI. We
included all variables that showed statistical significance in univariate analysis and relevant
factors associated with antithrombotic therapy in AF as covariates in the regression model.
Collinearity was evaluated between the covariates, confirming no significant correlations.
Individual model fitness was assessed using Hosmer–Lemeshow goodness-of-fit test.
All statistical analyses were performed using SAS software, version 9.3 (SAS Institute,
Cary, NC, USA), and a two-tailed p-value < 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics
A total of 5044, 7209, and 6438 patients were included in the pre-NOAC, transition,
and NOAC eras, respectively. Baseline characteristics of the three cohorts are summarized
in Table 1. Patients in the pre-NOAC era were younger and had a lower comorbidities
burden than those in the other cohorts. The CHA2DS2-VASc score (median (interquartile
range)) was lowest for patients in the pre-NOAC era (3 (2–5)) and highest for those in the
NOAC era (4 (2–5)). Baseline OACs prescription rates were 24.9%, 26.9%, and 35.2% in
pre-NOAC, transition, and NOAC eras, respectively. The rate of NOACs was 0.4% in the
pre-NOAC era, which significantly increased to 22.3% in the NOAC era. Triple therapy
was the major type of combination regimen at baseline (24.3%, 26.2%, and 34.2%). In the
NOAC era, NOAC were preferred over VKA as combination regimens in triple therapy
(21.5% vs. 12.7%) and double therapy (0.7% vs. 0.1%). Most of the patients received DAPT
without OAC at baseline (73.3%, 71.4%, and 63.6%) in all three cohorts. High DAPT rates
at baseline were prominent among patients with previous MI (75.4%, 75.9%, and 66.6%)
and those with peripheral artery disease (PAD) (74.9%, 73.6%, and 65.0%).
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Table 1. Baseline characteristics of the study population.
(A) Pre-NOAC
Era (n = 5044)
(B) Transition
Era (n = 7209)
(C) NOAC
Era (n = 6438) A vs. B A vs. C B vs. C
Demographics
Age, years 71 (63–77) 72 (63–78) 72 (63–78) 0.007 <0.001 0.434
Age groups <0.001 <0.001 0.105
<65 years 1420 (28.2) 2056 (28.5) 1846 (28.7)
65–74 years 1885 (37.4) 2444 (33.9) 2080 (32.3)
≥75 years 1739 (34.5) 2709 (37.6) 2512 (39.0)
Women 1775 (35.2) 2449 (34.0) 2167 (33.7) 0.487 0.259 0.999
Comorbidities
Diabetes Mellitus 2041 (40.5) 2867 (39.8) 2516 (39.1) 0.999 0.398 0.999
Hypertension 4500 (89.2) 6503 (90.2) 5770 (89.6) 0.223 0.999 0.777
Dyslipidemia 4023 (79.8) 6173 (85.6) 5626 (87.4) <0.001 <0.001 0.008
Congestive Heart Failure 1891 (37.5) 3064 (42.5) 3053 (47.4) <0.001 <0.001 <0.001
Myocardial Infarction 1876 (37.2) 2895 (40.2) 2746 (42.7) 0.003 <0.001 0.009
Peripheral Arterial Disease 1360 (27.0) 1946 (27.0) 1824 (28.3) 0.999 0.312 0.243
Stroke/TIA/Systemic Thromboembolism 897 (17.8) 1196 (16.6) 1043 (16.2) 0.253 0.074 0.999
Intracranial Hemorrhage 43 (0.9) 52 (0.7) 39 (0.6) 0.999 0.358 0.999
Gastrointestinal Bleeding 443 (8.8) 580 (8.0) 458 (7.1) 0.440 0.003 0.121
Renal Disease 863 (17.1) 1407 (19.5) 1323 (20.5) 0.002 <0.001 0.397
Liver Disease 1816 (36.0) 2656 (36.8) 2600 (40.4) 0.999 <0.001 <0.001
CHA2DS2-VAS score 3 (2–5) 4 (2–5) 4 (2–5) 0.018 <0.001 0.012
0 83 (1.6) 108 (1.5) 84 (1.3)
1 541 (10.7) 671 (9.3) 587 (9.1)
2 946 (18.8) 1310 (18.2) 1121 (17.4)
3 998 (19.8) 1465 (20.3) 1206 (18.7)
4 874 (17.3) 1244 (17.3) 1141 (17.7)
5 or higher 1602 (31.8) 2411 (33.4) 2299 (35.7)
Modified HAS-BLED score 3 (3–4) 3 (3–4) 3 (3–4) 0.645 0.024 0.363
1 163 (3.2) 200 (2.8) 179 (2.8)
2 827 (16.4) 1183 (16.4) 969 (15.1)
3 or higher 4054 (80.4) 5826 (80.8) 5290 (82.2)
Baseline Antithrombotic Therapy after
PCI
OACs overall 1256 (24.9) 1941 (26.9) 2263 (35.2) 0.036 <0.001 <0.001
VKAs 1235 (24.5) 1872 (26.0) 826 (12.8) 0.005 <0.001 <0.001
NOACs 21 (0.4) 69 (1.0) 1437 (22.3) 0.005 <0.001 <0.001
Triple therapy 1228 (24.3) 1886 (26.2) 2202 (34.2) 0.070 <0.001 <0.001
VKA-based 1207 (23.9) 1819 (25.2) 817 (12.7) 0.007 <0.001 <0.001
NOAC-based 21 (0.4) 67 (0.9) 1385 (21.5) 0.007 <0.001 <0.001
Double therapy (OACs + SAPT) 26 (0.5) 53 (0.7) 56 (0.9) 0.404 0.076 0.999
VKA-based 26 (0.5) 52 (0.7) 8 (0.1) 0.999 <0.001 <0.001
NOAC-based 0 (0.0) 1 (0.0) 48 (0.7) 0.999 <0.001 <0.001
DAPT 3697 (73.3) 5147 (71.4) 4093 (63.6) 0.063 <0.001 <0.001
Abbreviation: DAPT, dual antiplatelets; IQR, interquartile range; NOACs, non-vitamin K antagonist oral anticoagulants; OACs, oral
anticoagulants; PCI, percutaneous coronary intervention; SAPT, single antiplatelet; SD, standard deviation; TIA, transient ischemic attack;
VKAs, vitamin K antagonists. Values are given as median (interquartile range), or number (percentage), unless otherwise indicated.
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3.2. Two-Year Prescription Patterns in Antithrombotic Therapy after Percutaneous Coronary
Intervention
In all three cohorts, the overall rates of OACs were substantially low over two years
(18.5%, 22.5%, and 31.6% at 1-year period; 17.8%, 24.2%, and 31.8% at 2-year period in
pre-NOAC, transition, and NOAC eras, respectively) (Figure 1). At the 1-year period,
73.3%, 69.4%, and 60.7% of patients in each cohort received antiplatelet therapy without
OACs, most of which was DAPT (66.2%, 61.0%, and 52.8%). Similar rates were found at
the 2-year period at which time 61.9%, 54.7%, and 47.1% of patients in each cohort had
antiplatelet therapy without OACs (35.2%, 31.1%, and 26.5% were DAPT). The percentage
of patients who did not receive any antithrombotic treatment (the no-treatment group)
increased over 2 years; these percentages were 20.3%, 21.1%, and 21.1% at 2-year follow-up
in each cohort.
In terms of OACs regimens, triple therapy showed the highest proportions at 3-months
after PCI in all three cohorts (26.0%, 28.0%, and 36.5%), which decreased over two years
(10.1%, 10.1%, and 10.6% at 1-year period; 3.2%, 2.9%, and 2.9% at 2-year period). In
contrast, the rates were increased over two years for double therapy (7.0%, 10.9%, and
18.3% at 1-year period; 11.0%, 15.9%, and 20.0% at 2-year period), and OAC monotherapy
(1.4%, 1.5%, and 2.7% at 1-year period; 3.6%, 5.4%, and 8.9% at 2-year period). In the
pre-NOAC era, VKAs were the major type of OACs in all regimens. At the 1-year period,
52.6% of OACs prescriptions were VKA-based triple therapy (vs. 2.0% of NOACs-based
triple therapy), and 35.2% were VKA-based double therapy (vs. 2.5% of NOAC-based
double therapy). VKA monotherapy accounted for 6.8% of OACs prescriptions at the
1-year period (vs. 0.2% of NOAC monotherapy). From the pre-NOAC to the NOAC era,
the major type of OACs had been replaced from VKAs to NOACs. In the NOAC era, 42.5%
of OACs prescriptions at the 1-year period were NOAC-based double therapy (vs. 15.2%
of VKA-based double therapy), which increased to 47.9% (vs. 15.1%) at the 2-year period.
The NOAC monotherapy rate was 7.2% (vs. 1.5% of VKA monotherapy) at the 1-year
period, which increased to 24.6% (vs. 3.4%) at the 2-year period. When we compared the
OACs prescription rates between the three cohorts at each 3-month time interval, the rates
significantly increased from the pre-NOAC to the NOAC era (Figure 2). The proportions of
NOACs in overall OACs prescriptions were also significantly increased from pre-NOAC to
NOAC era. Table S2 summarizes the absolute numbers of patients with specific types of
antithrombotic therapy in each cohort. Sensitivity analysis excluding all censored cases
from the study population showed consistent patterns with those found in the main results
(Figure S1).
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Figure 1. Two-year patterns in antithrombotic therapy after percutaneous coronary intervention in patients with atrial 
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(B), and NOAC era (C). In all three cohorts, prescription rates of OACs were substantially low over the 2-year period, 
whereas DAPT was the major type of antithrombotic therapy after PCI. (left panel of A–C). VKAs were the dominant type 
of OACs in the pre-NOAC and transition era. However, NOACs were preferred to VKAs in all OACs regimens in the 
NOAC era (right panel of A–C). DAPT: dual antiplatelet therapy; OAC: oral anticoagulant; N: non-vitamin K oral antico-
agulant; PCI: percutaneous coronary intervention; SAPT: single antiplatelet therapy; W: warfarin. 
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Figure 2. Comparison of prescription rates of overall oral anticoagulants and non-vitamin K oral anticoagulants between 
the study cohorts. The figure shows the prescription rates of OACs (A) and the proportions of NOACs in overall OACs 
prescriptions (B) compared between the three cohorts in every 3-month time interval. In each period, the prescription rates 
of OACs and the proportions of NOACs were significantly increased from pre-NOAC to NOAC era. OACs: oral antico-
agulants; NOACs: non-vitamin K oral anticoagulants. 
3.3. Clinical Factors Associated with Oral Anticoagulants Use 1 Year after Percutaneous 
Coronary Intervention 
Old age (≥65 years), congestive heart failure, prior stroke or thromboembolism, and 
a high CHA2DS2-VASc score (≥2) were significantly associated with OACs use at the 1-
year period (Figure 3 and Table S3). Among the predictors, old age showed the strongest 
association with OACs use (odds ratio (OR) 1.69, 95% confidence interval(CI) 1.42–2.01). 
In contrast, female sex, MI, PAD, dyslipidemia, and chronic liver or renal disease were 
significantly associated with no OACs use at the 1-year period, of which previous MI 
showed the strongest association (OR 0.70, 95% CI 0.62–0.79). 
Figure 2. Comparison of prescription rates of overall oral anticoagulants and non-vitamin K oral anticoagulants between
the study cohorts. The figure shows the prescription rates of OACs (A) and the proportions of NOACs in overall OACs
prescriptions (B) compared between the three cohorts in every 3-month time interval. In each period, the prescription
rates of OACs and the proportions of NOACs were significantly increased from pre-NOAC to NOAC era. OACs: oral
anticoagulants; NOACs: non-vitamin K oral anticoagulants.
3.3. Clinical Factors Associated with Oral Anticoagulants Use 1 Year after Percutaneous Coronary
Intervention
Old age (≥65 years), congestive heart failure, prior stroke or thromboembolism, and
a high CHA2DS2-VASc score (≥2) were significantly associated with OACs use at the
1-year period (Figure 3 and Table S3). Among the predictors, old age showed the strongest
association with OACs use (odds ratio (OR) 1.69, 95% confidence interval(CI) 1.42–2.01).
In contrast, female sex, MI, PAD, dyslipidemia, and chronic liver or renal disease were
significantly associated with no OACs use at the 1-year period, of which previous MI
showed the strongest association (OR 0.70, 95% CI 0.62–0.79).
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Figure 3. Clinical factors associated with preference for oral anticoagulants use 1 year after percutaneous coronary
intervention. Old ge (≥65 years), previous congestive heart failure, stroke or thromboembolism, and a high CHA2DS2-
VASc score (≥2) were associated with OACs use at the 1-year period. In contrast, female sex, previous myocardial infarction,
peripheral arterial disease, dyslipidemia, chronic liver or renal disease were associated with no OACs use at the 1-year
period. CI: confidence interval; OACs: oral anticoagulants; PCI: percutaneous coronary intervention.
3.4. Clinical Factors Associated with a Preference for Oral Anticoagulant Monotherapy 1 Year after
Percutaneous Coronary Intervention
With regard to specific antithrombotic therapy regimens, a history of GI bleeding was
significantly associated with a preference for OAC monotherapy over combination regi-
mens 1 year after PCI, and dyslipidemia was associated with a preference f r combination
regimens (Figure 4A and Table S4). A history of MI and dyslipidemi was asso iated with a
prefer ce for antiplatelet-only thera y over OAC monoth rapy 1 year after PCI (Figure 4B
and Table S5). Notably, a history of GI bleeding was associated with a preference for OAC
monotherapy.
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regimens or antiplatelet-only therapy 1 year after percutaneous coronary intervention. Among the clinical factors, previous
gastrointestinal bleeding was associated with a preference for OAC monotherapy over combination regimens, whereas
dyslipidemia was associated with a preference for combination regimens (A). Previous gastrointestinal bleeding was also
associated a preference for OAC monotherapy than antiplatelet-only therapy. However, previous MI and dyslipidemia
were associated with a preference for antiplatelet-only therapy (B). CI: confidence interval; OAC: oral anticoagulant; PCI:
percutaneous coronary intervention.
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4. Discussion
NOACs are considered the mainstay of therapy for stroke prevention in patients with
AF, and a growing body of evidence has reported beneficial outcomes with a NOAC-based
combination regimen for patients with AF who undergo PCI [7–10]. Therefore, after PCI,
guidelines recommend NOAC administration in preference to VKAs in patients who are
eligible to receive NOACs as combination therapy that includes antiplatelet agents [1,2].
The current study investigated whether the updated guidelines have led to changes in
the long-term treatment patterns of antithrombotic therapy among patients with AF who
undergo PCI. We observed that the overall OAC prescription rate during the 2-year follow-
up period after PCI significantly increased from the pre-NOACs to the NOAC era. However,
the OAC prescription rate remained low after PCI in all three cohorts, and most patients
received antiplatelet therapy without OACs. Our results highlight the significant gap
between the current guidelines and real-world clinical practice, even after the transition to
the NOAC era.
We observed that predictors of bleeding risk, including chronic liver and renal disease,
were significantly associated with OAC non-use 1 year after PCI. Studies have reported
that ethnicity may affect the bleeding risk associated with antithrombotic therapy; the risk
is higher in Asian than in Western populations [11]. Based on our findings, we suggest that
fear of bleeding events following combination therapy may discourage healthcare providers
from prescribing OAC therapy over prolonged periods after PCI [12,13]. However, insuf-
ficient anticoagulation in patients with AF would further increase the thromboembolic
risk [13]. Therefore, it is important to maintain a careful balance between the thromboem-
bolic and bleeding risks, particularly in Asian patients with AF. A shorter duration of
combination therapy based on the individual bleeding risks in addition to strategies to
minimize PCI-induced bleeding (e.g., radial artery access) could be a useful approach for
reducing bleeding complications [1,2].
Factors associated with a high risk of ischemic events often serve as predictors of major
bleeding [14]. We observed that age and previous stroke were strongly associated with OAC
use 1 year post-PCI. Moreover, these two factors have coincidentally been incorporated as
components of the HAS-BLED score (an indicator of overall bleeding risk) [15]. Therefore,
the positive trend observed with the HAS-BLED score for OAC therapy 1 year after PCI is
attributable to the positive association between OAC therapy and age, as well as previous
stroke. The increasing burden of risk factors for both thromboembolic and bleeding events
is a major drawback that interferes with adherence to guideline-based antithrombotic
therapy in clinical practice [14]. In view of the high rate of stent thrombosis or recurrent MI
in the early phase after PCI, DAPT without OAC therapy or the use of novel antiplatelet
agents over a short period could be considered to maximize the effectiveness of DAPT and
to minimize the bleeding risk following the use of a combination regimen [16]. However,
such strategies are not currently recommended by the guidelines, and to date, there is a
lack of data to directly compare DAPT with a combination regimen in patients with AF
who undergo PCI. Therefore, clinicians should follow evidence-based treatment guidelines
and use an individualized approach based on patients’ thromboembolic and bleeding risks.
We observed that the baseline DAPT prescription rate was higher in patients with old
MI or a history of peripheral artery disease. We have previously reported a negative associ-
ation between vascular disease and triple antithrombotic therapy after PCI in patients with
AF [4]. After PCI, those who received DAPT without OACs were significantly associated
with OAC non-use 1 year after PCI [5]. Our current finding highlights trends observed
in real-world clinical practice, which show a preference for maintenance of antiplatelet
therapy without OACs in patients with a history of vascular disease. A significant burden
of coronary disease or complex PCI procedures in patients with vascular disease could also
affect the preference for antiplatelet therapy over a combination regimen after PCI [17].
However, studies have confirmed the beneficial outcomes of NOAC-based combination
therapy, regardless of coronary lesion characteristics or procedural complexities [18].
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Generally, triple therapy is recommended for 1–6 months after PCI, based on the
patient’s risk of ischemia and bleeding [1,2]. However, bleeding risks that are known to be
associated with triple therapy have led to the development of a new treatment regimen
that comprises double antithrombotic therapy but excludes aspirin from the combination
regimen [19]. After the introduction of NOACs, four randomized trials have reported
that post-PCI NOAC-based double therapy is superior to VKA-based triple therapy with
regard to bleeding events after PCI [7–10]. More recent evidence that supports double
therapy has been adopted in the updated guidelines as a treatment option for patients
with a high bleeding risk [1,2]. We observed a significant increase in the OAC prescription
rates over 2-year post-PCI follow-up from the pre-NOAC to the NOAC era, which could
be attributed to the increase in the percentage of NOAC prescriptions. High rates of
post-PCI NOAC-based antithrombotic therapy have also been observed in other Asian
populations [20,21]. In Korea, the reimbursement criteria for NOAC prescriptions in
patients with AF were expanded in 2015, which could have contributed to the increase in the
NOAC prescription rates in patients with AF who undergo PCI. However, 33.6% of patients
who were administered OACs continued to receive triple therapy 1 year after PCI. This
suggests a preference for 1-year post-PCI maintenance DAPT even after the widespread
availability of NOACs, which resulted in overtreatment and noncompliance with the
guideline recommendations [1,2]. Compared with double therapy, such overtreatment
with prolonged triple therapy increases bleeding risk without additional benefit in reducing
thromboembolic risk [22].
Following the administration of combination therapy using OACs and antiplatelet
agents, life-long anticoagulation with OAC monotherapy for stroke prevention is recom-
mended 1 year after PCI [1,2]. We observed a significantly low rate of OAC monotherapy
1 year after PCI in all three cohorts. Recently, the Atrial Fibrillation and Ischemic events
with Rivaroxaban in patiEnts with stable coronary artery disease (AFIRE) study reported
that rivaroxaban monotherapy was superior to combined therapy containing a single
antiplatelet drug for bleeding risk and was non-inferior with regard to the risk of ischemia
in patients with AF and stable coronary disease [23]. The Optimizing Antithrombotic
Care in patients with AtriaL fibrillatiON and coronary stEnt (OAC-ALONE) trial that
investigated patients with AF beyond 1 year post-PCI with coronary stenting compared the
benefits of OAC monotherapy with a combination regimen [24]. However, the results were
underpowered for the primary endpoint owing to early trial termination due to delayed
enrollment. We observed that a history of MI and dyslipidemia was associated with a pref-
erence for antiplatelet-only therapy over OAC monotherapy at 1-year follow-up. However,
OAC monotherapy was preferred over combination regimens in patients with a history
of gastrointestinal (GI) bleeding. These results highlight a tendency observed in clinical
practice to maintain antiplatelet therapy beyond 1 year after PCI for secondary prevention
in those with MI but not in patients with bleeding events. AF in patients who undergo
PCI is associated with advanced coronary disease [25]; therefore, healthcare providers are
hesitant to discontinue antiplatelet therapy 1 year after PCI. Further studies are necessary
to guide optimal antithrombotic therapy beyond 1 year after PCI in patients with AF.
Our results should be interpreted with caution owing to the following limitations of
this study: (a) Owing to the non-randomized study design, we could not control actual
patient compliance with prescribed medications across the study population. However, to
our knowledge, the current study is the largest study that has investigated 2-year longitu-
dinal patterns in antithrombotic therapy after PCI in patients with AF; this fact serves as a
strength of this research. (b) The association between changes in OAC treatment patterns
and long-term clinical outcomes were not investigated in this study. Future studies are
necessary to investigate the clinical outcomes associated with different types of antithrom-
botic therapies in patients with AF who undergo PCI. (c) Indications for PCI, such as acute
MI or stable angina, may affect the DAPT prescription rate. In this study, we selected
patients with AF who underwent PCI from the claims database based on procedure codes.
Therefore, we speculate that our study population would include patients with a variety of
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indications for PCI, including MI. (d) Up to 20% of patients did not receive any antithrom-
botic therapy at the 2-year follow-up period after PCI. A similar trend was reported by
a previous nationwide study performed during the VKA era, which included 16.5% of
patients with no antithrombotic therapy at the 2-year follow-up [5]. These results could be
attributed to ethnic differences in the bleeding risk associated with antithrombotic therapy;
the risk is higher among Asian than among Western patients [11]. We speculate that owing
to the well-known risk of bleeding events associated with combination regimens, healthcare
providers might be hesitant to continue prescribing OAC or antiplatelet therapy after PCI.
Additionally, poor compliance with guideline-based antithrombotic treatment observed in
clinical practice (which could be associated with a fear of bleeding complications) may at
least partly contribute to the increase in the percentage of patients included in the post-PCI
no-treatment group. However, data regarding major bleeding outcomes were unavailable
in our study; therefore, we could not determine the exact percentage of patients included
in the no-treatment group who truly developed bleeding complications. (e) The severity of
coronary lesions and complexities of PCI procedures may affect baseline OAC prescription
rates after PCI. However, information regarding the detailed coronary lesion characteristics
and PCI procedures was unavailable in the HIRA database. Moreover, data regarding
laboratory test results, such as serum creatinine levels are unavailable in the HIRA database;
therefore, we could not confirm the label adherence to NOACs.
5. Conclusions
We observed low OAC prescription rates in Asian patients with AF who underwent
PCI, even after the introduction of NOACs. Although the NOAC-based antithrombotic
therapy prescription rates increased, most patients continued to receive antiplatelet therapy
without OACs over the 2-year post-PCI follow-up. We observed a preference for prolonged
DAPT, even in combination with OACs as triple therapy.
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